Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biodynamics Plc LSE:OBD London Ordinary Share GB00BD5H8572 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.75 1.08% 70.50 17,570 16:35:08
Bid Price Offer Price High Price Low Price Open Price
68.00 73.00 68.50 68.50 68.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.46 -4.91 -4.70 65
Last Trade Time Trade Type Trade Size Trade Price Currency
16:10:06 O 5,000 69.51 GBX

Oxford Biodynamics (OBD) Latest News

More Oxford Biodynamics News
Oxford Biodynamics Investors    Oxford Biodynamics Takeover Rumours

Oxford Biodynamics (OBD) Discussions and Chat

Oxford Biodynamics Forums and Chat

Date Time Title Posts
02/2/202119:01Oxford BioDynamics PLC214

Add a New Thread

Oxford Biodynamics (OBD) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Oxford Biodynamics trades in real-time

Oxford Biodynamics (OBD) Top Chat Posts

Oxford Biodynamics Daily Update: Oxford Biodynamics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OBD. The last closing price for Oxford Biodynamics was 69.75p.
Oxford Biodynamics Plc has a 4 week average price of 67p and a 12 week average price of 64p.
The 1 year high share price is 104.50p while the 1 year low share price is currently 47p.
There are currently 92,559,771 shares in issue and the average daily traded volume is 80,669 shares. The market capitalisation of Oxford Biodynamics Plc is £65,254,638.56.
yellowstoneadvisory: If you are interested in the area of epigenetics and personalised medicine come along to the OBD webinar tomorrow evening at 5.30pm. New CEO Jon Burrows will talk about the progress made over the last year and the exciting prospects for 2021. A covid 19 disease severity test is due to launch this quarter which will identify the risks of a severe outcome, requiring intensive care treatment, from catching Covid. This diagnostic test will use blood samples and is suitable for use before catching the virus. Later in the year the company plans to launch an Immuno Oncology test for cancer patients to determine the response from various treatments. Progress is also being made with the Master Service agreement with a major US Pharma company and on its project with Mitsubishi Tanabe. Register here hxxps://
the ghost who walks: Poor share price reaction yesterday, any idea why?
rambutan2: Also: Matthew Wakefield, the new Chairman, said: "I have been associated with the company for well over a decade and I am convinced now more than ever of the considerable potential in the EpiSwitch(TM) technology. I am looking forward to leading the Board as Chairman and working with Jon and the team in this next phase of the Company's growth."
rambutan2: Noted: Oxford, UK - 15 December 2020 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch (TM) 3D genomics platform, announces the expansion of its strategic focus. Since his appointment in March 2020, the Company's new CEO, Dr Jon Burrows, has been assessing Oxford BioDynamics' business, its EpiSwitch(TM) technology, and ways in which the Company can unlock its considerable growth potential and bring its technology pipeline rapidly into the precision medicine market.
rambutan2: Unsure how relevant re dates and quite where OBD work fits in to timeline: htTps://
sjames1: Interesting how the price has been creeping better. Perhaps news of Covid work with Glasgow University imminent?
jaws6: most we know but good Q & A afterwards on Covid, contract in US , and few on this too Https://
astralvision: Webinar next week with OBD, could be interesting.You ain't going to do one unless you've got something good to say!
hamidahamida: Missed out on nyct obd try MWG a COVID19 player still capped below 10m Business has started to boom ..I feel now that media around the world has started talking about covid19 in waste water #MWG wil do a NCYT type of share price surge bcz its dominant position in waste water and sewage testing for viruses with its thousands of installed Microtox test systems around the world soon to be retrofitted with #AI real time alerts for COVID19 and other viruses...GB these studies are done, how do you put in place a permanent real-time alert system? BBC News - Coronavirus: Sewage study could predict second Covid-19 peak
hedgehog 100: OBD is looking very oversold at just 52.5p, and due a recovery like many other biotechs recently. It has a strong cash position: £15.5M. as at 30.9.19, compared to a full year pre-tax loss of just £3.386M. And personalised medicine could have an important role to play in tackling coronavirus, considering how coronavirus's effect, and the effect of its treatment, appears to vary according to a persons's genetics. "Coronavirus symptoms: Susceptibility to COVID-19 could be genetic - experts CORONAVIRUS infections could be targeting people more genetically predisposed towards COVID-19, researchers have claimed. By SEBASTIAN KETTLEY PUBLISHED: 21:28, Fri, Mar 20, 2020 | UPDATED: 23:00, Fri, Mar 20, 2020 ... The researchers told the Polish Press Agency (PAP) certain genetic characteristics or variations can affect how people react to COVID-19 and medication. ..." From OBD's website home page:- "INNOVATION SAVING LIVES We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification. EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine. Technology to select the right drug at the right dose at the right time for the right patient. EpiSwitch TM Accelerated development of companion diagnostics for the pharmaceutical industry." HTTP:// From OBD's final results to 30.9.19, released 10.12.19: " ... Corporate and operational highlights ▪ Continued development of EpiSwitch™ biomarkers for use in immuno-oncology (IO), including signing of fifth commercial collaboration. ... "
Oxford Biodynamics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210301 01:42:50